These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 8787544)
1. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Aherne GW; Hardcastle A; Raynaud F; Jackman AL Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540 [TBL] [Abstract][Full Text] [Related]
4. Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay. Horowitz RW; Zhang H; Schwartz EL; Ladner RD; Wadler S Biochem Pharmacol; 1997 Sep; 54(5):635-8. PubMed ID: 9337081 [TBL] [Abstract][Full Text] [Related]
5. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676 [TBL] [Abstract][Full Text] [Related]
6. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030 [TBL] [Abstract][Full Text] [Related]
7. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. Rutenber EE; Stroud RM Structure; 1996 Nov; 4(11):1317-24. PubMed ID: 8939755 [TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. Aherne GW; Ward E; Lawrence N; Dobinson D; Clarke SJ; Musgrove H; Sutcliffe F; Stephens T; Jackman AL Br J Cancer; 1998; 77(2):221-6. PubMed ID: 9460992 [TBL] [Abstract][Full Text] [Related]
9. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism. Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737 [TBL] [Abstract][Full Text] [Related]
11. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783 [TBL] [Abstract][Full Text] [Related]
13. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Temmink OH; Hoogeland MF; Fukushima M; Peters GJ Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590 [TBL] [Abstract][Full Text] [Related]
14. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series. Marsham PR; Jackman AL; Barker AJ; Boyle FT; Pegg SJ; Wardleworth JM; Kimbell R; O'Connor BM; Calvert AH; Hughes LR J Med Chem; 1995 Mar; 38(6):994-1004. PubMed ID: 7699716 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP. Almog R; Waddling CA; Maley F; Maley GF; Van Roey P Protein Sci; 2001 May; 10(5):988-96. PubMed ID: 11316879 [TBL] [Abstract][Full Text] [Related]
16. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Ward WH; Kimbell R; Jackman AL Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289 [TBL] [Abstract][Full Text] [Related]
17. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. Phan J; Koli S; Minor W; Dunlap RB; Berger SH; Lebioda L Biochemistry; 2001 Feb; 40(7):1897-902. PubMed ID: 11329255 [TBL] [Abstract][Full Text] [Related]
18. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs. Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629 [TBL] [Abstract][Full Text] [Related]
19. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Drake JC; Allegra CJ; Moran RG; Johnston PG Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551 [TBL] [Abstract][Full Text] [Related]